来源：新浪证券-红岸工作室 10月10日，五洲医疗跌2.73%，成交额6404.62万元，换手率2.15%，总市值29.61亿元。 异动分析 医疗器械概念+人民币贬值受益+专精特新 1、公司主营业务为一次性使用无菌输注类医疗器械的研发、生产、销售以及其他诊断、护理等相关医 疗用品的集成供应，产品为一次性使用无菌注射器(带针)、一次性使用无菌注射器(不带针)、一次性使 用无菌胰岛素注射器、输液器、输血器、注射针、胰岛素注射笔用针头、输液针、采血针、血压表、面 罩、导尿管。 今日主力净流入-368.88万，占比0.06%，行业排名97/131，该股当前无连续增减仓现象，主力趋势不明 显；所属行业主力净流入-3848.00万，连续2日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入-368.88万-384.57万231.56万1735.53万155.38万 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额1822.42万，占总成交额的5.8%。 技术面：筹码平均交易成本为43.20元 该股筹码平均交易成本为43.20元，近期筹码关注程度减弱；目前股价靠近支撑位42.00，注意支撑位处 反弹，若跌 ...

来源：新浪证券-红岸工作室 9月30日，华人健康跌0.86%，成交额4027.14万元，换手率2.12%，总市值50.64亿元。 异动分析 医药电商+医疗器械概念+养老概念+阿里巴巴概念+创新药 1、据2023年2月17日互动易回复：公司除阿里旗下的天猫/饿了么平台外，公司在京东/拼多多/美团等国 内主要电商平台也都有布局，并且报告期内取得了长足发展。 2、安徽华人健康医药股份有限公司的主营业务是从事医药零售、代理及终端集采业务。公司的主要产 品是中成西药、中药饮片、保健品、医疗器械、特色原料。 资金分析 今日主力净流入-224.28万，占比0.06%，行业排名14/32，该股当前无连续增减仓现象，主力趋势不明 显；所属行业主力净流入-2.48亿，连续3日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入-224.28万-1036.09万-301.80万-4945.41万-8468.28万 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额2042.28万，占总成交额的2.04%。 技术面：筹码平均交易成本为14.02元 该股筹码平均交易成本为14.02元，近期该股有吸筹现象，但吸筹力度不强； ...

异动分析 医疗器械概念+辅助生殖+人民币贬值受益 来源：新浪证券-红岸工作室 9月26日，采纳股份跌1.25%，成交额4813.76万元，换手率2.60%，总市值29.90亿元。 1、公司主营业务为从事注射穿刺器械及实验室耗材的研发、生产和销售。公司目前主要产品为穿刺 针、注射器、实验室耗材及口罩等。 2、公司采纳医疗于2018年开始向Thermo Fisher 供应试管婴儿培育管产品。 3、根据2024年年报，公司海外营收占比为90.61%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-187.34万，占比0.04%，行业排名70/131，连续2日被主力资金减仓；所属行业主力净流 入-6.04亿，当前无连续增减仓现象，主力趋势不明显。 区间今日近3日近5日近10日近20日主力净流入-187.34万-741.67万-2607.78万-4266.65万-4035.66万 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额3092.47万，占总成交额的8.28%。 技术面：筹码平均交易成本为23.47元 该股筹码平均交易成本为23 ...

Core Viewpoint - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., is actively expanding its presence in the health sector, particularly focusing on elderly care and innovative pharmaceutical products, while facing fluctuations in stock performance and market interest [2][3][8]. Company Overview - Anhui Huaren Health Pharmaceutical Co., Ltd. was established on June 29, 2001, and listed on March 1, 2023. The company primarily engages in pharmaceutical agency, retail, and terminal procurement, with its main revenue derived from traditional Chinese and Western medicine, accounting for 97.60% of total revenue [7]. - The company is located in Hefei, Anhui Province, and operates within the pharmaceutical and biological industry, specifically in the pharmaceutical commercial sector, focusing on offline pharmacies [7]. Business Strategy - The company is strategically positioning itself in the silver-haired health sector by providing chronic disease training and services through pharmacies, aiming to enhance health management for the elderly [2]. - It is developing a series of products targeting common diseases among the elderly, including the "Fuman Medical" series for cardiovascular health and the "Guojin" series of traditional Chinese medicine for health maintenance [2][3]. Financial Performance - For the first half of 2025, the company reported a revenue of 2.504 billion yuan, representing a year-on-year growth of 15.52%, and a net profit attributable to shareholders of 104 million yuan, up 42.17% from the previous year [8]. - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [8]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 45.15% to 26,100, with an average of 5,725 shares held per person, a decrease of 31.10% [8]. - Alibaba Health is the second-largest shareholder, holding 7.51% of the company, and there are collaborations with various Alibaba platforms [3][8]. Market Activity - On September 26, the company's stock price fell by 1.01%, with a trading volume of 42.49 million yuan and a market capitalization of 5.08 billion yuan [1]. - The stock has shown no clear trend in major net inflows, with a net outflow of 8.27 million yuan on the day [4][5].

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is experiencing a decline in stock price but has strong fundamentals and growth potential in the medical device sector, particularly in endoscopic instruments and optical products [1][2]. Company Overview - Qindao Haitai New Light was established on June 11, 2003, and went public on February 26, 2021. The company specializes in the research, development, production, and sales of medical endoscopic instruments and optical products [7]. - The revenue composition of the company includes 64.86% from medical endoscopic instruments, 21.63% from optical products, 13.09% from maintenance services, and 0.42% from leasing [7]. - As of June 30, 2025, the company reported a revenue of 266 million yuan, representing a year-on-year growth of 20.50%, and a net profit of 74.44 million yuan, with a growth of 5.52% [7]. Market Position and Recognition - The company is recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for small and medium-sized enterprises that excel in niche markets and possess strong innovation capabilities [2]. - The company has a vertical integration capability from core components to system integration, making it one of the few in the domestic market with such capabilities [2]. Financial Performance - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8]. - As of June 30, 2025, the number of shareholders increased by 18.87% to 5,285, while the average circulating shares per person decreased by 16.39% to 22,682 shares [7]. International Exposure - The company benefits from a significant overseas revenue share, which accounted for 69.12% of total revenue in the 2024 annual report, positively impacted by the depreciation of the Chinese yuan [3].

Core Viewpoint - Anhui Huaren Health Pharmaceutical Co., Ltd. is actively expanding its presence in the senior health sector, focusing on chronic disease management and developing products tailored for elderly health needs [2][3]. Company Overview - Anhui Huaren Health Pharmaceutical Co., Ltd. was established on June 29, 2001, and went public on March 1, 2023. The company is primarily engaged in pharmaceutical agency, retail, and terminal procurement, with its main revenue derived from traditional Chinese and Western medicine, accounting for 97.60% of total revenue [7]. - As of June 30, 2023, the company had 26,100 shareholders, an increase of 45.15% from the previous period, with an average of 5,725 circulating shares per person, a decrease of 31.10% [8]. Financial Performance - For the first half of 2023, the company achieved a revenue of 2.504 billion yuan, representing a year-on-year growth of 15.52%. The net profit attributable to shareholders was 104 million yuan, up 42.17% year-on-year [8]. - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [8]. Market Position and Shareholder Structure - The company has a market capitalization of 5.132 billion yuan, with a trading volume of 57.7375 million yuan and a turnover rate of 3.00% on September 25, 2023 [1]. - Alibaba Health is the second-largest shareholder, holding 7.51% of the company, and there are collaborations with various Alibaba platforms [3]. Strategic Initiatives - The company is focusing on the senior health market by providing chronic disease training and services through pharmacies, enhancing health consultation and medication guidance for the elderly [2]. - It is developing a series of products aimed at common diseases in the elderly, including the "Fuman Medical" series for cardiovascular health and the "Guojin" series of traditional Chinese medicine health products [2][3].

来源：新浪证券-红岸工作室 3、根据2024年年报，公司海外营收占比为69.12%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入670.78万，占比0.06%，行业排名15/131，连续2日被主力资金增仓；所属行业主力净流 入8238.33万，连续2日被主力资金增仓。 区间今日近3日近5日近10日近20日主力净流入670.78万700.09万93.02万-761.28万220.42万 主力持仓 9月25日，海泰新光涨3.90%，成交额1.10亿元，换手率1.84%，总市值60.31亿元。 异动分析 医疗器械概念+专精特新+人民币贬值受益 1、公司始终致力于将光学技术与医疗器械行业的前沿应用趋势相结合，研究发展高性能的尖端内窥镜 器械产品。目前，公司是国内少有的具备从核心部件、关键设备到系统集成的行业垂直整合能力的企 业。 2、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升 ...

Core Viewpoint - The company, Zhonghong Medical, is experiencing growth in its overseas revenue, benefiting from the depreciation of the RMB and focusing on innovative medical products for diverse market needs [4][3]. Group 1: Company Overview - Zhonghong Medical specializes in the research, production, and sales of high-quality medical and industrial disposable protective gloves, with a revenue composition of 89.48% from health protection products, 6.22% from safety infusion products, and 4.30% from innovative incubation products [9]. - The company was established on December 22, 2010, and went public on April 27, 2021, with its headquarters located in Tangshan, Hebei Province [9]. Group 2: Financial Performance - For the first half of 2025, Zhonghong Medical achieved a revenue of 1.238 billion yuan, representing a year-on-year growth of 7.76%, while the net profit attributable to shareholders decreased by 82.35% to 5.7429 million yuan [10]. - The company has distributed a total of 1.251 billion yuan in dividends since its A-share listing, with 501 million yuan distributed over the past three years [11]. Group 3: Market Position and Trends - The company operates primarily through ODM direct sales, producing medical devices and consumables for overseas brand owners, which allows it to maintain a strong export focus [2]. - As of June 30, 2025, the company had a total market capitalization of 5.785 billion yuan, with a trading volume of 36.8624 million yuan on September 24, 2025 [1]. Group 4: Product Innovation and Development - Zhonghong Medical is committed to innovation, continuously launching high-performance medical products to meet diverse market demands, and integrating digital technology into product development for smart upgrades [3]. - The company showcased its veterinary infusion pumps at the 12th Beijing Pet Expo, highlighting their safety and multifunctionality, which received positive feedback from veterinary professionals [2].

Core Viewpoint - The company, 港通医疗, is experiencing a decline in stock performance and has reported significant decreases in revenue and net profit for the first half of 2023, indicating potential challenges ahead [8]. Company Overview - 港通医疗, established on January 13, 1998, is located in Chengdu, Sichuan Province, and was listed on July 25, 2023. The company specializes in providing medical gas systems and clean operating room solutions for medical institutions [7]. - The company's main business revenue composition includes: 55.69% from clean medical equipment and systems, 37.30% from medical gas equipment and systems, 4.06% from medical device sales, 2.81% from operation and maintenance services, and 0.14% from other sources [8]. Financial Performance - For the first half of 2023, 港通医疗 reported revenue of 265 million yuan, a year-on-year decrease of 39.29%, and a net profit attributable to shareholders of -8.4044 million yuan, a year-on-year decrease of 154.53% [8]. - The company has cumulatively distributed 48.9973 million yuan in dividends since its A-share listing [9]. Market Activity - On September 23, 港通医疗's stock fell by 1.99%, with a trading volume of 35.9516 million yuan and a turnover rate of 2.80%, resulting in a total market capitalization of 2.073 billion yuan [1]. - The stock has seen a net outflow of 270,100 yuan from major investors today, with a continuous reduction in major funds over the past three days [4][5]. Strategic Developments - 港通医疗 has developed the 港通云监测平台, which utilizes advanced IoT technology for real-time monitoring of medical equipment in hospitals [3]. - The company plans to repurchase shares with a total fund of no less than 50 million yuan and no more than 100 million yuan, with a maximum price of 28.49 yuan per share, funded by its own resources and a special loan from Bank of China [3]. Industry Position - 港通医疗 has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title for small and medium-sized enterprises in China, indicating its strong market position and innovation capabilities [3].

Core Viewpoint - The company, Zhonghong Medical, is primarily engaged in the export of medical devices and consumables, utilizing an ODM direct sales model, which allows it to design and produce products for overseas brand owners [2][4]. Group 1: Company Overview - Zhonghong Medical is a state-owned enterprise controlled by the Xiamen Municipal Government State-owned Assets Supervision and Administration Commission [5]. - The company was established on December 22, 2010, and went public on April 27, 2021. Its main business includes the research, production, and sales of high-quality nitrile gloves, PVC gloves, and other disposable protective gloves [9]. - As of June 30, 2025, the company had 20,200 shareholders, with an average of 19,502 circulating shares per person, reflecting a 0.40% increase in shareholder numbers [10]. Group 2: Financial Performance - For the first half of 2025, Zhonghong Medical achieved a revenue of 1.238 billion yuan, representing a year-on-year growth of 7.76%. However, the net profit attributable to shareholders decreased by 82.35% to 5.7429 million yuan [10]. - The company's overseas revenue accounted for 81.56% of total revenue, benefiting from the depreciation of the RMB [4]. Group 3: Product and Market Development - At the 12th Beijing Pet Expo, Zhonghong Medical showcased its innovative veterinary infusion pumps, which received positive feedback for their safety and multifunctionality [2]. - The company emphasizes innovation and digital technology integration in product development, aiming to become a leading provider of intelligent medical solutions [3]. Group 4: Market Activity - On September 23, Zhonghong Medical's stock fell by 1.76%, with a trading volume of 80.3791 million yuan and a turnover rate of 1.54%, resulting in a total market capitalization of 5.73 billion yuan [1]. - The average trading cost of the stock is 14.67 yuan, with the current price approaching a resistance level of 13.54 yuan, indicating potential for upward movement if this level is surpassed [8].